Safety and efficacy of the multidrug resistance inhibitor incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 670-678

  Toppmeyer, Deborah ^a   Seidman, Andrew D ^b   Pollak, Michael ^c   Russell, Christy ^d   Tkaczuk, Katherine ^e   Verma, Shailendra ^f   Overmoyer, Beth ^g   Garg, Varun ^h   Ette, Ene ^h   Harding, Matthew W ^h   Demetri, George D ⁱ  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f OTTAWA REGIONAL CANCER CENTRE   (Canada)

^g LERNER RESEARCH INSTITUTE   (United States)

^h VERTEX PHARMACEUTICALS   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIRICODAR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RECURRENT CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PACLITAXEL; PIPERIDINES; PYRIDINES; SAFETY; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 0036300981     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Treatment of breast cancer
2. The taxanes; an update
3. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer
4. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer
5. Paclitaxel activity in heavily pretreated breast cancer; a National Cancer Institute treatment referral center trial
6. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
7. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
8. Multicenter, randomized comparative study with two doses of paclitaxel in patients with metastatic breast cancer
9. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
10. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National surgical adjuvant breast and bowel project protocol B-26
11. Molecular mechanisms of resistance to taxanes and therapeutic implications
12. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations
13. Predominant labeling of β-over α-tubulin from porcine brain by a photoactivatable taxoid derivative
14. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death
15. Paclitaxel induces programmed cell death in MDAMB-468 human breast cancer cells
16. Multidrug resistance: Molecular mechanisms and clinical relevance
17. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
18. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance
19. Levels of multidrug resistance (MDR1) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to Taxol and Doxorubicin
20. Functional imaging of multidrug-resistant p-glycoprotein with an organotechnetium complex
21. Fractional retention of technetium-99m-sestamibi as an index of p-glycoprotein expression in untreated breast cancer patients
22. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi-scan in untreated breast cancer patients
23. 99mTc-sestamibi uptake in malignant tumors
24. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
25. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
26. VX-710 (VX-710; Incel): An effective chemosensitizer in neuroblastoma
27. Phase I and pharmacokinetic study of paclitaxel in combination with VX-710, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
28. Design and conduct of clinical trials
29. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
30. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
31. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
32. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103
33. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
34. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion
35. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic study in metastatic breast cancer
36. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype
37. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
38. Clinical trials of P-glycoprotein reversal in solid tumours
39. Clinical relevance of transmembrane drug efflux is a mechanism of multidrug resistance
40. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial
41. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer
42. Phase II trial of dexverapamil and epirubicin in patients with nonresponsive metastatic breast cancer
43. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen
44. Doseintensive vinorelbine with concurrent granulocyte colony stimulating factor support in paclitaxel-refractory metastatic breast cancer
45. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
46. Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
47. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
48. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
49. Expression of multidrug resistance-related transporters in human breast carcinoma
50. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209, and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
51. A multidrug resistance transporter from MCF-7 breast cancer cells
52. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells
53. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells
54. Resistance mechanisms in human sarcoma mutants derived by single step exposure to paclitaxel (Taxol)
55. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
56. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes
57. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters β-tubulin isotype expression
58. Palitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel driven polymerization
59. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance
60. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations
61. The biochemistry of apoptosis
62. Molecular effects of paclitaxel: Myths and reality (a critical review)
63. Deletion of the loop region of Bcl-2 completely blocks paclitaxely-induced apoptosis
64. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together